Address: | 300 Connell Dr Suite 3100, Berkeley Heights, NJ 07922, USA |
---|---|
Postal code: | 07922 |
Phone: | (908) 516-1350 |
Website: | http://www.chugai-pharm.com/ |
Monday: | 9:00 AM – 5:00 PM |
---|---|
Tuesday: | 9:00 AM – 5:00 PM |
Wednesday: | 9:00 AM – 5:00 PM |
Thursday: | 9:00 AM – 5:00 PM |
Friday: | 9:00 AM – 5:00 PM |
Saturday: | Closed |
Sunday: | Closed |
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Chugai Pharma USA, Inc., use the form below and your opinion, advice or comment will appear in this space.
+1 908-516-1350 Share this site; Back to Top. Chugai Pharma USA, Inc. takes great care over the information presented on this website, but it does not guarantee its ...
Chugai Pharma USA, Inc. 300 Connell Drive, Suite 3100, Berkeley Heights, NJ 07922 (908) 516-1350 Careers: www.chugai-pharm.com/jobs
Chugai Pharma USA, Inc. (CPUSA) is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd., one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products.
Hours Do you know the hours for this business? Location Connell Corporate Ctr III AKA. Chugai Usa, Inc. Chugai Pharma USA LLC. Chugai Pharma USA, Inc. Other Link
For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com. For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1 ...
Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai originated innovative new drug candidates.
For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com. For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1 ...
TOKYO--(BUSINESS WIRE)--Mar 14, 2019--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche received the decision from the European Commission confirming that Hemlibra ® (emicizumab) , a hemophilia A treatment originated by Chugai, has EU marketing authorization for routine ...